In Vino Veritas (IVV): a pilot randomised trial comparing long-term effects of red wine and white wine on the biomarkers of atherosclerosis

In Vino Veritas (IVV) a long-term, prospective, multicentre, randomised trial comparing long-term effects of red wine and white wine on the biomarkers of atherosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN54359610

Enrollment

120

Registered

2010-12-20

Start date

2010-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary prevention of atherosclerosis in individuals at mild to moderate Circulatory System Atherosclerosis

Interventions

Eligible individuals will be randomised to regular drinking of either red wine (Pinot Noir, 2008, Moravia, Czech Republic) or white wine (Chardonnay-Pinot, 2008, Moravia, Czech Republic) for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age over 18 years 2. No symptoms of atherosclerosis 3. Mild to moderate risk of cardiovascular disease

Exclusion criteria

Exclusion criteria: 1. Acute or chronic inflammatory disease 2. Liver disease 3. Renal disease

Design outcomes

Primary

Measure	Time frame
Level of high density lipoprotein (HDL) cholesterol, measured at 6 and 12 months.	—

Secondary

Measure	Time frame
1. Total and low density lipoprotein (LDL) cholesterol 2. Triglycerides 3. Oxidized LDL 4. C-reactive protein (CRP) 4. Advanced oxidation protein product (AOPP) 5. Myeloperoxidase 6. Interleukin 6 (IL-6) 7. IL-18 8. Matrix metalloproteinases 9. Glutathione s-transferase 10. Monocyte chemoattractant protein 1 11. Solube CD40L 12. Fatty acid binding protein Outcomes will be measured at 6 and 12 months.	—

Measure

Time frame

1. Total and low density lipoprotein (LDL) cholesterol 2. Triglycerides 3. Oxidized LDL 4. C-reactive protein (CRP) 4. Advanced oxidation protein product (AOPP) 5. Myeloperoxidase 6. Interleukin 6 (IL-6) 7. IL-18 8. Matrix metalloproteinases 9. Glutathione s-transferase 10. Monocyte chemoattractant protein 1 11. Solube CD40L 12. Fatty acid binding protein Outcomes will be measured at 6 and 12 months.

—

Countries

Czech Republic

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026